

**IMMUNOMODULATORS, ATOPIC DERMATITIS PRIOR AUTHORIZATION FORM** (form effective 1/8/2024)

Prior authorization guidelines for **Immunomodulators, Atopic Dermatitis and Quantity Limits/Daily Dose Limits** are available on the DHS Pharmacy Services website at <https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/default.aspx>.

<input type="checkbox"/> New request <input type="checkbox"/> Renewal request		# of pages: _____	Prescriber name:	
Name of office contact:			Specialty:	
Contact's phone number:			NPI:	State license #:
LTC facility contact/phone:			Street address:	
Beneficiary name:			City/state/zip:	
Beneficiary ID#:	DOB:	Phone:	Fax:	

**CLINICAL INFORMATION**

Drug requested:	Strength:	Dosage form:	
Directions:		Quantity:	Refills:
Diagnosis ( <i>submit documentation</i> ):		Diagnosis code ( <i>required</i> ):	

**Complete all sections that apply to the beneficiary and this request.**  
***Check all that apply and submit documentation for each item.***

**INITIAL requests**

- For a non-preferred topical calcineurin inhibitor:**  
 Tried and failed or has a contraindication or an intolerance to the preferred topical calcineurin inhibitors (*Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred drugs in this class.*)
- For a topical JAK inhibitor (eg, Opzelura [ruxolitinib]) OR a topical PDE4 inhibitor (eg, Eucrisa [crisaborole]):**  
 Tried and failed or has a contraindication or an intolerance to a 4-week trial of a topical corticosteroid approved or medically accepted for the beneficiary's diagnosis  
 Tried and failed or has a contraindication or an intolerance to an 8-week trial of a topical calcineurin inhibitor (eg, pimecrolimus, tacrolimus) approved or medically accepted for the beneficiary's diagnosis
- For all other non-preferred TOPICAL Immunomodulators, Atopic Dermatitis:**  
 Tried and failed or has a contraindication or an intolerance to the preferred topical Immunomodulators, Atopic Dermatitis approved or medically accepted for the beneficiary's diagnosis (*Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred drugs in this class.*)
- For a targeted systemic Immunomodulator, Atopic Dermatitis (eg, Adbry, Cibinqo, Rinvoq):**  
 Is prescribed the medication by or in consultation with an appropriate specialist (eg, dermatologist)  
 **For the treatment of atopic dermatitis:** Tried and failed or has a contraindication or an intolerance to both of the following (*check all that apply*):

- One of the following:
- For the face, skin folds, or other critical areas, a 4-week trial of a low-potency (or higher) topical corticosteroid
  - For other body areas, a 4-week trial of a medium potency or higher topical corticosteroid
  - An 8-week trial of a topical calcineurin inhibitor (eg, pimecrolimus, tacrolimus)

For the treatment of all other diagnoses – specify diagnosis: \_\_\_\_\_

List other treatments tried (including start/stop dates, dose, outcomes, etc.): \_\_\_\_\_

For an **oral JAK inhibitor** (eg, Cibinqo, Rinvoq):

- Tried and failed at least one biologic as recommended in the JAK inhibitor's package labeling
- Has a contraindication or an intolerance to biologics as recommended in the JAK inhibitor's package labeling
- Is currently taking an oral JAK inhibitor

For a **NON-PREFERRED targeted systemic Immunomodulator, Atopic Dermatitis:**

- Tried and failed or has a contraindication or intolerance to the preferred targeted systemic Immunomodulators, Atopic Dermatitis approved or medically accepted for the beneficiary's condition (Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred drugs in this class.)
- Is currently using the requested non-preferred targeted systemic Immunomodulator, Atopic Dermatitis

- What is the date of the beneficiary's last dose? \_\_\_\_\_

**RENEWAL requests**

**1. For a non-preferred topical calcineurin inhibitor:**

- Has documented evidence of improvement of disease severity
- Tried and failed or has a contraindication or an intolerance to the preferred topical calcineurin inhibitors (Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred drugs in this class.)

**2. For a topical JAK inhibitor (eg, Opzelura [ruxolitinib]) OR a topical PDE4 inhibitor (eg, Eucrisa [crisaborole]):**

- Has documented evidence of improvement of disease severity

**3. For all other non-preferred TOPICAL Immunomodulators, Atopic Dermatitis:**

- Has documented evidence of improvement of disease severity
- Tried and failed or has a contraindication or an intolerance to the preferred topical Immunomodulators, Atopic Dermatitis approved or medically accepted for the beneficiary's diagnosis (Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred drugs in this class.)

**4. For a targeted systemic Immunomodulator, Atopic Dermatitis (eg, Adbry, Cibinqo, Rinvoq):**

- Has documented evidence of improvement of disease severity
- Is prescribed the medication by or in consultation with an appropriate specialist (eg, dermatologist)

**PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION**

**Prescriber Signature:**

**Date:**

**Confidentiality Notice:** The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.